A low-dose combination of valsartan and low molecular weight heparin better improved glomerular permeability than did high-dose monotherapy in rats with diabetic nephropathy

Drug Discoveries & Therapeutics

Volumn 5, Issue 3, 2011, Pages 119-124

  Jiao, Bo ^a   Zhang, Yahui ^a,b   Cheng, Yanna ^a   Gao, Jianjun ^a   Zhang, Qingzhu ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85008738395     PISSN: 18817831     EISSN: 1881784X     Source Type: Journal    
DOI: 10.5582/ddt.2011.v5.3.119     Document Type: Article

References (25)

1. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999; 34:795-808.
2. Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev. 2005; 1:27-40.
3. Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Curr Diabetes Rev. 2011; 7:3-7.
4. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000; 57:590-600.
5. Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun. 2003; 300:16-22.
6. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994; 93:2431-2437.
7. Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H. Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy. Kidney Blood Press Res. 2010; 33:213-220.
8. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006; 1:221-228.
9. Yang SY, Hu ZY, Cao H, Yang T, Yu GH. Effect of angiotensin II receptor antagonist on renin-angiotensin system in main organs of spontaneously hypertensive rats. Chinese Circulation Journal. 2000; 15:56-58.
10. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini AP, Baggio B. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992; 42:285-291.
11. Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: Implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008; 31(Suppl 2):S202-S207.
12. van der Pijl JW, van der Woude FJ, Geelhoed-Duijvestijn PH, Frolich M, van der Meer FJ, Lemkes HH, van Es LA. Danaparoid sodium lowers proteinuria in diabetic nephropathy. J Am Soc Nephrol. 1997; 8:456-462.
13. Weigert C, Brodbeck K, Haring HU, Gambaro G, Schleicher ED. Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int. 2001; 60:935-943.
14. Saxena B. Anti-hyperlipidemic activity of Withania coagulans in streptozotocininduced diabetes: A potent anti-atherosclerotic agent. Drug Discov Ther. 2010; 4:334-340.
15. Srivastava S, Gupta A, Agarwal GG, Natu SM, Uma S, Goel MM, Srivastava AN. Correlation of serum vascular endothelial growth factor with clinicopathological parameters in cervical cancer. BioSci Trends. 2009; 3:144-150.
16. Matsumoto-Takasaki A, Horie J, Sakai K, Furui Y, Sato R, Kawakami H, Toma K, Takayanagi A, Shimizu N, Fujita-Yamaguchi Y. Isolation and characterization of anti-T-antigen single chain antibodies from a phage library. BioSci Trends. 2009; 3:87-95.
17. Nishi H, Inoue Y, Kageshita T, Takata M, Ihn H. The expression of human high molecular weight melanoma-associated antigen in acral lentiginous melanoma. BioSci Trends. 2010; 4:86-89.
18. Santos GA, Cunha IW, Rocha RM, Mello CA, Guimaraes GC, Fregnani JH, Lopes A. Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. BioSci Trends. 2010; 4:25-30.
19. Henry S, Bigler S, Wang J. High throughput analysis of neural progenitor cell proliferation in adult rodent hippocampus. BioSci Trends. 2009; 3:233-238.
20. Amorim RF, Godoy GP, Galvao HC, Souza LB, Freitas RA. Immunohistochemical assessment of extracellular matrix components in syndrome and non-syndrome odontogenic keratocysts. Oral Dis. 2004; 10:265-270.
21. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 2003; 14:274-281.
22. Liebau MC, Lang D, Bohm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstadt H, Fischer KG. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006; 290:F710-719.
23. Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, Choi HY, Kim JS, Kim HJ, Han SH, Lee JE, Han DS, Kang SW. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int. 2007; 71:1019-1027.
24. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008; 73:163-171.
25. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990; 346:371-374.